Navigation Links
Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
Date:3/28/2008

ment and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC"). These statements have not been evaluated by the Food and Drug Administration. Resurgex(R), Resurgex Plus(R), Resurgex Select(R) and Surgex(TM) are not intended to diagnose, treat, cure, or prevent and disease.


'/>"/>
SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Smart Medical Technology, Inc. Awarded Novation Contract for Ground-breaking Liftaem(TM) System that Aids Lifting and Transferring Patients
4. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
5. Environmental Operating Solutions Completes Initial Tranche of $2.5 Million Institutional Financing
6. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
7. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
8. Pharmos Corporation Completes Initial Closing of Private Placement
9. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
10. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
11. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), ... of targeted antiviral therapies, announced today that it will ... Annual Global Investment Conference sponsored by H.C. Wainwright ... The St. Regis Hotel in New York, ... , Chief Executive Officer, will provide an overview of ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... recombinant antibodies, announced today that the National Institutes of Health (NIH) has awarded ... will be administered by the NIH’s National Institute of Diabetes and Digestive and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the ... the opportunities for advanced analytics utilizing data lakes in the healthcare industry. , As ... seen an explosion of data over the last few years as more entities become ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... from University of California Los Angeles, Boston University School of Medicine, Frederick National ... in PLOS One, the world’s first multidisciplinary Open Access journal. , Christopher ...
Breaking Biology Technology:ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3
... YWCA & Roche to Educate Patients on, How ... a Career -, NEW YORK, March 10 ... a non-profit program,founded by Cosmetic Executive Women Foundation, and ... hundreds of thousands of people,living with cancer on how ...
... CITY, Calif., March 10, Otsuka Pharmaceutical Co., Ltd. ... today announced the closing of the,previously announced transaction ... Busulfex(R) (busulfan), including trademarks, patents,intellectual property and related ... Busulfex is an oncologic product marketed and sold ...
... - Interim analysis results expected in Q3 ... - Fralex Therapeutics Inc.,(TSX:FXI) ("Fralex" or the ... neuromodulation device, today announced the,randomization of the ... is a,multi-centre, double-blind placebo-controlled randomized clinical trial,designed ...
Cached Biology Technology:First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 2First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4Fralex reaches 100th patient milestone in fibromyalgia study 2Fralex reaches 100th patient milestone in fibromyalgia study 3
(Date:8/4/2015)... Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today reported ... 2015. Highlights: , Second quarter contract revenue ... 2014 , Adjusted contract margins of ... $0.22, including a $0.05 decrease in EPS from royalties in the ... million "We are very pleased to present another ...
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... COLLEGE STATION This time of year, the word "virus" ... everyone goes to great lengths to avoid. But scientists for ... least some viruses can be put to work to help us. ... Dr. Herman Scholthof, to be published in the January issue of ...
... BEER-SHEVA, ISRAEL January 4, 2010 - A researcher from ... integrated interpretation of Autism Spectrum Disorders (ASD), which makes ... between ASD and other conditions. In an ... The Neuroscientist titled: "The Medial Prefrontal Cortex and ...
... As it turns out, children were not the only ones ... this past holiday season. In a new research report published ... Leukocyte Biology ( http://www.jleukbio.org ), a team of scientists ... for Children show how a compound from licorice root (glycyrrhizin ...
Cached Biology News:Virus may chauffeur useful 'packages' into plants 2A trip to the candy store might help ward off rare, but deadly infections 2
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
... 2, Monoclonal Antibody, Unconjugated Applications: ... dilution. ICC: Use at an assay dependent dilution. ... 10 ug/ml, this concentration is determined using a ... 40 kDa. Not tested in other applications. ...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Anti human PPAR gamma2 mouse monoclonal antibody...
Biology Products: